KURA$8.91
$9.04
Chart
Performance
Key Stats
AI KURA Summary
Powered by LiveAIAI Scoreboard
Powered by LiveAIOverall Analysis
HoldKura Oncology shows mixed signals, with significant long-term thematic potential in oncology treatments but facing current fundamental and technical headwinds. Investors should monitor clinical trial progress and market sentiment.
Thematic
Kura Oncology operates in the highly impactful biopharmaceutical sector, with a focus on oncology, a critical area of medical need. Its pipeline targets genetically defined subsets of leukemias and solid tumors, aligning with advancements in precision medicine.
Fundamental
Kura Oncology's fundamentals are currently weak, characterized by significant losses, negative free cash flow, and a substantial drop in share price over the past year. The company holds considerable cash, but its ability to convert this into profitability remains a key concern.
Technical
Kura Oncology's technical indicators present a mixed picture. While some short-term oscillators suggest potential buying opportunities, the overall trend and longer-term moving averages indicate weakness, with the stock trading significantly below its 52-week high.
| Factor | Score |
|---|---|
| Oncology Drug Development | 85 |
| Biotechnology Innovation | 70 |
| Collaboration & Partnerships | 75 |
| Market Demand for Cancer Therapies | 80 |
| Regulatory Pathway | 65 |
| Factor | Score |
|---|---|
| Valuation | 30 |
| Profitability | 5 |
| Growth | 10 |
| Balance Sheet Health | 70 |
| Cash Flow | 70 |
| Factor | Score |
|---|---|
| Trend Analysis | 25 |
| Momentum | 45 |
| Moving Averages | 30 |
| Volume | 50 |
| Short-term Oscillators | 50 |
AI Investing Checklist
Powered by LiveAIBullish Points (6)
Strong Cash Position
The company has a significant cash and cash equivalents position of $224.46 million as of Q4 2024, providing ample liquidity to fund operations and strategic initiatives.
Manageable Debt Levels
As of Q4 2024, the company's total debt is $16.59 million, which is relatively low compared to its market capitalization of $534.17 million and cash reserves, indicating a healthy capital structure with low leverage risk.
Bearish Points (8)
Significant Net Losses and Negative EPS
The company has consistently reported substantial net losses, with a TTM net income of -$131.05 million and an EPS of -$2.09. This indicates ongoing unprofitability, a common characteristic of clinical-stage biopharma but a significant risk for investors.
Limited Revenue and Negative Growth
Revenue for 2023 was reported as $0, and for 2024 as $53.88 million. This lack of consistent, substantial revenue and the zero revenue in 2023 highlight the early-stage nature and high risk associated with commercialization.
Calendar
August 2025
6
Next Earnings Date
H: $0.18
A: $-0.41
L: $-0.86
H: 375.00M
A: 64.95M
0Profile
Kura Oncology, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. Its lead product candidate includes ziftomenib, a selective investigational inhibitor of the menin-KMT2A interaction for the treatment of genetically defined subsets of acute leukemias, including acute myeloid leukemia and acute lymphoblastic leukemia; tipifarnib, an orally bioavailable farnesyl transferase inhibitor combination with alpelisib for patients with PIK3CA-dependent HNSCC; and KO-2806, a selective investigational FTI for the treatment of solid tumors. It has a clinical collaboration with Novartis Pharma AG to evaluate the combination of tipifarnib and alpelisib in patients with head and neck squamous cell carcinoma whose tumors have HRAS overexpression and/or PIK3CA mutation and/or amplification; strategic collaboration agreement with Kyowa Kirin Co., Ltd. to develop and commercialize its oral menin inhibitor for the treatment of patients with acute myeloid leukemia (AML) and other hematologic malignancies; and a clinical collaboration with Mirati Therapeutics, Inc. to evaluate the combination of KO-2806 and adagrasib, a KRASG12C inhibitor in patients with NSCLC. The company is headquartered in San Diego, California.
Seasonals
Price Target
25.73 USD
The 39 analysts offering 1 year price forecasts for KURA have a max estimate of 40.00 and a min estimate of 8.00.
Debt Level and Coverage
Financial Position Analysis
Ownership
Capital Structure
Valuation - Summary
Valuation - Ratios
Revenue to Profit Conversion
Balance Sheet
Cash Flow
Related Companies
Powered by LiveAIWeight: 95
Directly competing in the Acute Myeloid Leukemia (AML) space, specifically targeting MLL-rearranged AML, similar to Kura Oncology's lead program, ziftomenib.
Weight: 88
Focuses on precision oncology and rare genetic diseases, with a pipeline that includes drugs for hematologic malignancies, aligning with Kura's precision medicine approach.
Weight: 85
A clinical-stage precision oncology company developing therapies for genetically defined cancers, reflecting a similar strategic focus on targeted therapeutics as Kura.
Weight: 82
Clinical-stage precision oncology company, primarily focused on pediatric cancers but with a similar drug development stage and emphasis on targeted therapies.